Sanofi $SNY Shares Sold by Cullen Capital Management LLC

Cullen Capital Management LLC trimmed its stake in shares of Sanofi (NASDAQ:SNY) by 6.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 360,777 shares of the company’s stock after selling 23,705 shares during the quarter. Cullen Capital Management LLC’s holdings in Sanofi were worth $17,483,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the business. Y Intercept Hong Kong Ltd raised its stake in shares of Sanofi by 310.4% during the 4th quarter. Y Intercept Hong Kong Ltd now owns 73,556 shares of the company’s stock worth $3,565,000 after buying an additional 55,631 shares in the last quarter. Wealthspire Advisors LLC increased its stake in Sanofi by 1,043.1% in the 4th quarter. Wealthspire Advisors LLC now owns 5,624 shares of the company’s stock valued at $273,000 after purchasing an additional 5,132 shares in the last quarter. Quadrant Capital Group LLC increased its position in Sanofi by 10.5% during the fourth quarter. Quadrant Capital Group LLC now owns 27,886 shares of the company’s stock worth $1,351,000 after buying an additional 2,650 shares in the last quarter. Laurel Oak Wealth Management LLC purchased a new position in Sanofi during the fourth quarter worth $371,000. Finally, Federation des caisses Desjardins du Quebec boosted its holdings in shares of Sanofi by 47.1% during the fourth quarter. Federation des caisses Desjardins du Quebec now owns 81,677 shares of the company’s stock worth $3,958,000 after purchasing an additional 26,134 shares during the last quarter. 14.03% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Up 0.3%

NASDAQ:SNY opened at $44.25 on Friday. The firm has a market capitalization of $107.28 billion, a PE ratio of 12.36, a price-to-earnings-growth ratio of 1.09 and a beta of 0.34. The stock has a 50 day moving average of $45.14 and a 200-day moving average of $46.55. Sanofi has a 52 week low of $42.28 and a 52 week high of $52.68. The company has a current ratio of 1.01, a quick ratio of 0.22 and a debt-to-equity ratio of 0.17.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which was paid on Wednesday, June 3rd. Stockholders of record on Monday, May 4th were issued a dividend of $2.4225 per share. This represents a dividend yield of 559.0%. This is a boost from Sanofi’s previous annual dividend of $2.04. The ex-dividend date of this dividend was Monday, May 4th. Sanofi’s dividend payout ratio is currently 49.16%.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Wall Street Zen cut Sanofi from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, March 19th. BNP Paribas Exane cut Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a research note on Monday, April 20th. Citigroup reaffirmed a “neutral” rating on shares of Sanofi in a research report on Monday, April 13th. Finally, Morgan Stanley set a $52.00 target price on Sanofi in a research report on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $51.00.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.